HCSGD entry for ACTG1
1. General information
| Official gene symbol | ACTG1 |
|---|---|
| Entrez ID | 71 |
| Gene full name | actin, gamma 1 |
| Other gene symbols | ACT ACTG BRWS2 DFNA20 DFNA26 |
| Links to Entrez Gene | Links to Entrez Gene |
2. Neighbors in the network
This gene isn't in PPI subnetwork.
3. Gene ontology annotation
GO ID | GO term | Evidence | Category |
|---|---|---|---|
| GO:0005200 | Structural constituent of cytoskeleton | IC IEA | molecular_function |
| GO:0005515 | Protein binding | IPI | molecular_function |
| GO:0005524 | ATP binding | IEA | molecular_function |
| GO:0005737 | Cytoplasm | IEA | cellular_component |
| GO:0005829 | Cytosol | TAS | cellular_component |
| GO:0005856 | Cytoskeleton | IEA TAS | cellular_component |
| GO:0006928 | Cellular component movement | TAS | biological_process |
| GO:0007411 | Axon guidance | TAS | biological_process |
| GO:0030016 | Myofibril | IEA | cellular_component |
| GO:0031941 | Filamentous actin | IEA | cellular_component |
| GO:0034329 | Cell junction assembly | TAS | biological_process |
| GO:0034332 | Adherens junction organization | TAS | biological_process |
| GO:0038096 | Fc-gamma receptor signaling pathway involved in phagocytosis | TAS | biological_process |
| GO:0042802 | Identical protein binding | IPI | molecular_function |
| GO:0045087 | Innate immune response | TAS | biological_process |
| GO:0045214 | Sarcomere organization | IEA | biological_process |
| GO:0045216 | Cell-cell junction organization | TAS | biological_process |
| GO:0070062 | Extracellular vesicular exosome | IDA | cellular_component |
Entries Per Page
Displaying Page of
4. Expression levels in datasets
- Meta-analysis result
| p-value up | p-value down | FDR up | FDR down |
|---|---|---|---|
| 0.9890696440 | 0.1813958588 | 0.9999902473 | 0.8254703320 |
- Individual experiment result
( "-" represent NA in the specific microarray platform )
( "-" represent NA in the specific microarray platform )
| Data source | Up or down | Log fold change |
|---|---|---|
| GSE11954 | - | - |
| GSE13712_SHEAR | - | - |
| GSE13712_STATIC | - | - |
| GSE19018 | - | - |
| GSE19899_A1 | - | - |
| GSE19899_A2 | - | - |
| PubMed_21979375_A1 | - | - |
| PubMed_21979375_A2 | - | - |
| GSE35957 | - | - |
| GSE36640 | - | - |
| GSE54402 | - | - |
| GSE9593 | - | - |
| GSE43922 | - | - |
| GSE24585 | - | - |
| GSE37065 | - | - |
| GSE28863_A1 | Down | -0.0665557850 |
| GSE28863_A2 | Down | -0.1880293476 |
| GSE28863_A3 | Up | 0.2597707901 |
| GSE28863_A4 | Down | -0.0117734312 |
| GSE48662 | Down | -0.6928310492 |
5. Regulation relationships with compounds/drugs/microRNAs
- Compounds
Not regulated by compounds
- Drugs
Not regulated by drugs
- MicroRNAs
- mirTarBase
- mirTarBase
MiRNA_name | mirBase ID | miRTarBase ID | Experiment | Support type | References (Pubmed ID) |
|---|---|---|---|---|---|
| hsa-let-7b-5p | MIMAT0000063 | MIRT001852 | Luciferase reporter assay//Reporter assay;Other | Non-Functional MTI | 15131085 |
| hsa-let-7b-5p | MIMAT0000063 | MIRT001852 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-16-5p | MIMAT0000069 | MIRT031957 | Proteomics | Functional MTI (Weak) | 18668040 |
| hsa-miR-16-5p | MIMAT0000069 | MIRT031957 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-1307-3p | MIMAT0005951 | MIRT035814 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-1180-3p | MIMAT0005825 | MIRT035953 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-1227-3p | MIMAT0005580 | MIRT036397 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-1226-3p | MIMAT0005577 | MIRT036487 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-935 | MIMAT0004978 | MIRT036673 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-877-3p | MIMAT0004950 | MIRT037047 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-877-5p | MIMAT0004949 | MIRT037360 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-744-5p | MIMAT0004945 | MIRT037421 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-423-5p | MIMAT0004748 | MIRT038157 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-99b-3p | MIMAT0004678 | MIRT038520 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-769-3p | MIMAT0003887 | MIRT039133 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-652-3p | MIMAT0003322 | MIRT039560 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-193b-3p | MIMAT0002819 | MIRT041197 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-331-3p | MIMAT0000760 | MIRT043297 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-326 | MIMAT0000756 | MIRT043651 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-342-3p | MIMAT0000753 | MIRT043711 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-361-5p | MIMAT0000703 | MIRT044076 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-99b-5p | MIMAT0000689 | MIRT044186 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-320a | MIMAT0000510 | MIRT044776 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-149-5p | MIMAT0000450 | MIRT045649 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-222-3p | MIMAT0000279 | MIRT046782 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-221-3p | MIMAT0000278 | MIRT046971 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-34a-5p | MIMAT0000255 | MIRT047350 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-10b-5p | MIMAT0000254 | MIRT047480 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-10a-5p | MIMAT0000253 | MIRT047724 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-197-3p | MIMAT0000227 | MIRT048069 | CLASH | Functional MTI (Weak) | 23622248 |
Entries Per Page
Displaying Page of
- mirRecord
No target information from mirRecord
- mirRecord
6. Text-mining results about the gene
Gene occurances in abstracts of cellular senescence-associated articles: 2 abstracts the gene occurs.
PubMed ID of the article | Sentenece the gene occurs |
|---|---|
| 27354367 | Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s |
| 22448010 | METHODS: We measured the percentage of CD28(-)CD4(+) and CD8(+) T cells from HIV-infected treatment-naive adults from 5 Adult Clinical Trials Group (ACTG) antiretroviral therapy (ART) studies and the ALLRT (ACTG Longitudinal Linked Randomized Trials) cohort, and from 48 HIV-negative adults |
Entries Per Page
Displaying Page of
